PIK3CA and breast cancer: Alpelisib has been approved by the FDA for the treatment of HER2-positive advanced breast cancer with a PIK3CA mutation, which increases the 7.9-month survival rate of patients with advanced breast cancer, according to a phase III clinical trial (NCT04208178) [132,133].